News Highlight Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…ractigenMarch 3, 2023
Company News Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer SUZHOU, Jiangsu, China -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been…ractigenJanuary 9, 2023
